Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Decreased by Parallel Advisors LLC

Parallel Advisors LLC lessened its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 58,569 shares of the medical research company's stock after selling 7,229 shares during the quarter. Parallel Advisors LLC's holdings in Edwards Lifesciences were worth $4,243,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of EW. GoalVest Advisory LLC raised its holdings in Edwards Lifesciences by 93.5% in the 1st quarter. GoalVest Advisory LLC now owns 1,248 shares of the medical research company's stock worth $90,000 after purchasing an additional 603 shares during the period. GAMMA Investing LLC raised its position in Edwards Lifesciences by 7,061.2% during the first quarter. GAMMA Investing LLC now owns 340,946 shares of the medical research company's stock worth $24,712,000 after acquiring an additional 336,185 shares during the period. AdvisorNet Financial Inc lifted its holdings in Edwards Lifesciences by 11.5% during the first quarter. AdvisorNet Financial Inc now owns 1,663 shares of the medical research company's stock valued at $121,000 after purchasing an additional 172 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after purchasing an additional 145 shares in the last quarter. Finally, Kera Capital Partners Inc. raised its position in shares of Edwards Lifesciences by 5.0% during the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock worth $224,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $0.29 during trading hours on Wednesday, reaching $78.01. The stock had a trading volume of 1,276,322 shares, compared to its average volume of 5,180,143. The firm has a 50-day moving average of $73.62 and a 200-day moving average of $72.60. The firm has a market cap of $45.76 billion, a price-to-earnings ratio of 11.19, a PEG ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the firm posted $0.66 earnings per share. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the sale, the vice president now owns 50,356 shares of the company's stock, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,012 shares of company stock worth $4,224,717. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on EW shares. Robert W. Baird upped their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. Barclays boosted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Truist Financial decreased their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $80.20.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.